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of cardiac and vascular structures was increased approxi-
mately 3-fold. Immuno fluorescent stainings showed EGFP 
expression exclusively in vascular-like structures simultane-
ously expressing von Willebrand factor and in formerly beat-
ing areas expressing   -actinin. Cx40-EGFP-expressing EBs 
revealed significantly higher numbers of beating cardiomy-
ocytes and vascular-like structures. Semiquantitative RT-
PCRs confirmed an enhanced cardiovascular differentiation 
as shown for the cardiac markers Nkx2.5 and MLC2v, as well 
as the endothelial marker vascular endothelial cadherin. 
 Conclusions: Our work shows the feasibility of specific label-
ing and purification of cardiovascular progenitor cells from 
differentiating EBs based on the Cx40 promoter. We provide 
proof of principle that the deleted CD4 (  CD4) surface mark-
er-based method for magnetic cell sorting developed by our 
group will be ideally suitable for transference to this pro-
moter.  Copyright © 2008 S. Karger AG, Basel 
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 Abstract 
 Background: Pluripotent embryonic stem (ES) cells that can 
differentiate into functional cardiomyocytes as well as vas-
cular cells in cell culture may open the door to cardiovascular 
cell transplantation. However, the percentage of ES cells in 
embryoid bodies (EBs) which spontaneously undergo car-
diovascular differentiation is low ( ! 10%), making strategies 
for their specific labeling and purification indispensable. 
 Methods: The human connexin 40 (Cx40) promoter was iso-
lated and cloned in the vector pEGFP. The specificity of the 
construct was initially assessed in  Xenopus embryos injected 
with Cx40-EGFP plasmid DNA. Stable Cx40-EGFP ES cell 
clones were differentiated and fluorescent cells were en-
riched manually as well as via fluorescence-activated cell 
sorting. Characterization of these cells was performed with 
respect to spontaneous beating as well as via RT-PCRs and 
immunofluorescent stainings.  Results: Cx40-EGFP reporter 
plasmid injection led to EGFP fluorescence specifically in the 
abdominal aorta of frog tadpoles. After crude manual en-
richment of highly Cx40-EGFP-positive EBs, the appearance 
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 Introduction 
 The identification and characterization of embryonic 
stem (ES) cells that can differentiate into functional car-
diomyocytes as well as vascular cells in cell culture may 
open the door to therapeutic cardiovascular cell trans-
plantation [Vittet et al., 1996; Nir et al., 2003; Gerecht-Nir 
et al., 2004]. Yet, the percentage of ES cells in embryoid 
bodies (EBs) which spontaneously undergo cardiovascu-
lar differentiation is low ( ! 10%) and highly dependent on 
the ES cell line used as well as on the serum lots available 
to the researcher. Additionally, ES cell-derived cardiomy-
ocytes terminate their cell cycle followed by formation of 
multinuclei – a typical feature of terminally differenti-
ated cardiomyocytes [Klug et al., 1996]. Therefore, the 
proliferative potential of ES-derived cardiomyocytes in 
vivo is probably limited and the availability of reasonable 
numbers of cardiomyocytes required to repair a myocar-
dial infarction in men ( 1 10 8 cells) appears to be a major 
prerequisite yet to be fulfilled for their clinical applica-
tion [Li et al., 1999]. At the same time, ES cell-derived 
cardiac tissue will require a sufficient blood supply via 
newly formed vasculature to warrant its survival in the 
host myocardium [Hunt, 1998].
 Problems yet to be solved for future ES cell-based car-
diac therapy comprise (1) reliably high cellular purities to 
avoid transplantation of undesired cell types leading to 
teratoma formation and (2) sufficient numbers of cardio-
vascular cells meant for transplantation. Methods such as 
fluorescence-activated cell sorting (FACS) or magnetic 
cell sorting (MACS) allow purification of specific cell 
types but are dependent on the expression of a specific 
surface marker that can be recognized by a fluorescent or 
magnetic microbead-tagged antibody. Yet, for many cell 
types such as cardiac and vascular cells an appropriate 
endogenous marker is not known. Therefore, sorting 
methods have to rely on the introduction of a marker 
gene under the control of a lineage-specific promoter. In 
such an effort we have previously labeled and FACS puri-
fied ventricular cardiomyocytes expressing enhanced 
green fluorescent protein (EGFP) [Muller et al., 2000] 
and subsequently developed a protocol for MACS allow-
ing rapid isolation of highly purified viable ES cell-de-
rived cell types [David et al., 2005].
 A novel candidate to transfer our approach to com-
mon cardiovascular progenitor cells is the promoter of 
the connexin 40 (Cx40) gene. In the fetal mammalian 
heart, Cx40 is expressed in ventricular and atrial myo-
cytes as well as in the ventricular conduction system 
[Teunissen and Bierhuizen, 2004]. In addition, endothe-
lial cells express Cx40, whereas smooth muscle cells ex-
press Cx43 or Cx45 [Simon and McWhorter, 2002]. 
Therefore, the Cx40 promoter may provide a useful tool 
to target marker gene expression to cardiovascular de-
rivatives of differentiating ES cells [Seul et al., 1997].
 During ES cell differentiation, Cx40 mRNA is ex-
pressed at days 3–8 of EB formation [Oyamada et al., 1996]. 
This background prompted us to perform our analyses at 
day 6 of differentiation, the earliest possible time point at 
which EGFP labeling allowed high yields of positive cells 
representing putative early cardiovascular precursors.
 Materials and Methods 
 Plasmid Construction 
 The human 4.9-kb Cx40 promoter was amplified from human 
genomic DNA via proof-reading PCR using Pfu polymerase 
(Stratagene). Primers for cloning of the Cx40 promoter fragment 
contained Kpn1 and Age1 restriction sites. Subsequently, the PCR 
product was inserted into pEGFP (Clontech) after digestion with 
these 2 enzymes. In detail, the primers were: 5  -GATggtacc-
GAAAAACACTGGCCGTGTAG-3  (forward primer, Kpn1 site 
in lower case characters) and 5  -CTATaccggt C TTGGCACAGC-
CAGGGAAC-3  (backward primer; Age1 site in lower case char-
acters). The C (in bold) in the backward primer corresponds to
–1 bp of the Cx40 coding region. After sequencing, this vector was 
used for electroporation of GSES cells and subsequent selection of 
stable clones.
 Xenopus  Injections 
 Xenopus embryos were injected with 100 pg of Cx40-EGFP 
plasmid DNA at the 2-cell stage into 1 blastomere according to 
standard protocols [David et al., 1998]. As injection volume, 5 nl 
was used. Embryos were obtained by in vitro fertilization, culti-
vated and injected as described previously [David et al., 1998]. 
Embryos were kept in 1 ! modified Barth’s saline solution hold-
ing medium until 2–5 h after injection and then transferred to 
0.1 ! modified Barth solution holding medium. Staging was per-
formed according to the normal table of Nieuwkoop and Faber. 
Embryos exhibiting GFP fluorescence were sorted using a Zeiss 
epifluorescence microscope.
 ES Cell Culture and Clone Selection 
 Electroporation and isolation of stable clones using the mu-
rine ES cell line GSES were performed according to standard pro-
tocols with minor modifications [Muller et al.,  2000]. Thereby, 5 
  g nonlinearized vector was used for electroporation (240 V/500 
  F) of 5  ! 10 6 GSES cells. Transgenic ES cells were grown in 
high-glucose Dulbecco’s modified Eagle medium supplemented 
with 10% heat-inactivated ES cell-qualified fetal calf serum, 2 m M 
 L -glutamine, 50 U/ml penicillin, 50   g/ml streptomycin, 1 ! non-
essential amino acids, 0.4 mg/ml geneticin (G418; all reagents 
from Gibco BRL) and 0.1 m M   -mercaptoethanol (Sigma). Anti-
biotic treatment was performed for 20 days before clonal expan-
sion. Subsequently, stable lines were identified via genomic PCR 
using primers corresponding to the transfected plasmid. Primer 
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sequences were: 5  -GACAACCACTACCTGAGCAC-3  (forward 
primer) and 5  -CATTCCACAGCTGGTTCTTTCC-3  (back-
ward primer). PCRs from positive clones yielded an amplified 
DNA fragment of the expected length (997 bp).
 ES cell clones were kept undifferentiated under feeder-free 
conditions by addition of 1,000 U/ml purified recombinant mouse 
leukemia inhibitory factor (ESGRO; Life Technologies Inc.). Cells 
were maintained at 37 ° C in a humidified atmosphere of 5% 
CO 2 /95% air. Monolayers were passaged by trypsinization at con-
fluence of 70–80%. For FACS, differentiated cells were dissoci-
ated using PBS containing 5 m M EDTA as described below. In 
vitro differentiation was initiated as follows: GSES cells were har-
vested with 0.25% trypsin-EDTA and dissociated cells were trans-
ferred to bacteriological dishes at a density of 2  ! 10 5 ES cells/ml 
in Iscove’s modified Eagle medium (Sigma) supplemented with 
10% heat-inactivated fetal calf serum, 2 m M  L -glutamine, 50 U/ml 
penicillin, 50   g/ml streptomycin, 1 ! nonessential amino acids 
(all reagents from Life Technologies Inc.) and 450   M   -mono-
thioglycerol (Sigma). After 2 days, EBs were transferred to new 
medium. At day 6, EBs with a similar size were plated onto gela-
tin-coated tissue culture dishes. The growth medium for the at-
tached differentiation cultures was changed every day.
 Reverse Transcription Polymerase Chain Reaction 
 Semiquantitative RT-PCR incorporating   32 P-dCTP was per-
formed according to standard protocols using RNA isolated from 
5  ! 10 4 FACS-purified or unpurified cells at day 6 of differentia-
tion via the RNeasy Kit (Qiagen). The amplified murine cDNA 
fragments corresponded to bp 64–189 of H4, to bp 454–557 of Cx40, 
to bp 1332–1454 of Nkx2.5, to bp 5–260 of MLC2v and to bp 65–270 
of vascular endothelial cadherin. The annealing temperature was 
57 ° C for all primer pairs, and the number of cycles used was be-
tween 28 and 33. The radioactive PCR products were separated on 
7.5% polyacrylamide gels and analyzed using a phosphorimager.
 Flow Cytometry 
 For FACS analysis of EGFP expression, the cells were dissoci-
ated in PBS containing 5 m M EDTA for 15 min at 37 ° C after wash-
ing them twice in PBS without calcium. Subsequently, the cells 
were spinned down at 2,500 rpm for 3 min in an Eppendorf cen-
trifuge and resuspended in 100   l ice-cold PBS containing 2% 
BSA. FACS analyses were performed with an Epics XL (Beckman-
Coulter) using the evaluation program EXPO32ADC.
 Fluorescence Microscopy 
 Adherent EBs were rinsed 3 times with PBS and fixed with 4% 
paraformaldeyhde for 30 min at room temperature. The fixed 
cells were washed twice. Unspecific binding sites were blocked by 
PBS containing 20% bovine serum and 0.05% Tween 20 for 1 h. 
Primary antibodies anti-von Willebrand factor (Santa Cruz; dilu-
tion 1: 100) and anti-  -actinin (Sigma; dilution 1: 250) were ap-
plied without washing and incubated for 30 min at 37 ° C with 
gentle shaking. After washing, cells were incubated with a Cy3-
conjugated goat anti-rabbit-IgG monoclonal antibody for 1 h. All 
dilutions of antibodies were prepared in PBS containing 20% goat 
serum. Controls of autofluorescence or nonspecific fluorescence 
were performed on fixed cells processed without the secondary 
and primary antibody. Monolayers were mounted in Mowiol and 
examined using a Zeiss Axiovert fluorescence microscope.
 Results 
 We first isolated a 4.9-kb fragment of the human 
Cx40 promoter and inserted it in pEGFP (Clontech) to 
enable cardiovascular-specific EGFP expression ( fig. 
1 a). We subsequently used this construct for injections 
Cx40 promoter
Kpn1 Age1 Not1
MCS
pEGFP backbone
4.9 kb
a
b
********
c
*
EGFP
 Fig. 1.  a DNA construct used for in vitro 
translation and stable expression of EGFP 
under control of the human 4.9-kb Cx40 
promoter in  Xenopus embryos and murine 
ES cells.  b EGFP fluorescence in the ab-
dominal aorta of a stage 45 tadpole previ-
ously injected with 100 pg Cx40-EGFP 
plasmid at the 2-cell stage. Scale bar cor-
responds to 200   m.  c Identification of 
stable Cx40-EGFP-transfected murine ES 
cell clones via genomic PCR using primers 
specific for the transfected plasmid. Black 
asterisks = Positive clones revealing the 
expected band of 997 bp; white asterisk = 
positive control using the plasmid as tem-
plate DNA. 
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in  Xenopus embryos, a convenient screening system 
routinely performed by our group to test for the func-
tionality of promoter fragments or overexpressed fac-
tors [David et al., 2005]. We thereby found EGFP fluo-
rescence specifically in the abdominal aorta of stage 45 
tadpoles ( fig. 1 b), indicating a very high conservation of 
regulatory elements within the 4.9-kb promoter frag-
ment between higher and lower vertebrates. This en-
couraging observation prompted us to proceed with 
electroporations of murine ES cells. After subsequent 
clone selection using 0.4 mg/ml geneticin (G418) for 20 
days, 8 stable lines were identified via genomic PCR 
with primers specific for the transfected plasmid ( fig. 1 c). 
The cells were induced to differentiate and analyzed for 
EGFP positivity via fluorescence microscopy after 6 
days ( fig. 2 a, b). Typically, at that time point the EBs 
showed either large EGFP-positive areas or remained 
mainly EGFP negative (see asterisks in  fig. 2 a, b). FACS 
analyses at day 13 confirmed the visually obtained re-
sults and revealed positive fractions of 12–18% of cells 
within the EBs ( fig. 2 c, d). For further analysis, 2 of the 
clones were used in analytic FACS to define the time 
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 Fig. 2. Functionality of the Cx40-EGFP marker construct in stably 
transfected ES cells.  a ,  b EGFP-positive EBs of 2 independent 
clones at day 6 of differentiation in suspension culture. Asterisks 
indicate EBs weakly expressing EGFP. Scale bars correspond to 
100   m.  c ,  d FACS analysis of dissociated Cx40-EGFP-positive 
EBs derived from the same clones 13 days after differentiation, 
showing an EGFP-positive fraction of 8 and 17%.  e Time course 
of EGFP expression in the same 2 clones analyzed by FACS. GSES 
cells served as control.  f RT-PCR at day 6 of differentiation: strong 
enrichment of endogenous murine Cx40 mRNA after FACS puri-
fication of Cx40-EGFP-positive cells. GSES cells served as con-
trol. 
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course of EGFP expression under control of the 4.9-kb 
Cx40 promoter fragment. We thereby found very weak 
expression at the onset of differentiation, yet a subse-
quent strong increase in Cx40-EGFP-positive cells up to 
day 20 when the maximal fluorescence was reached 
( fig. 2 e). To verify the functionality of the 4.9-kb human 
Cx40 promoter fragment in murine ES cells, we then 
performed preparative FACS followed by RT-PCRs for 
endogenous murine Cx40 mRNA expression which was 
dramatically enriched in the Cx40-EGFP-positive frac-
tions ( fig. 2 f).
 These results were confirmed on the protein level via 
immunofluorescent stainings showing EGFP expression 
exclusively in vascular-like structures simultaneously ex-
pressing von Willebrand factor ( fig. 3 a–d) and in former-
ly beating areas expressing   -actinin ( fig. 3 e–h).
 Based on these results, we next asked whether the 4.9-
kb Cx40 promoter may be a suitable tool to isolate pure 
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 Fig. 4. Enrichment of Cx40-EGFP-positive 
cells by manual isolation leads to enhanced 
cardiovasculogenesis.  a Three-fold en-
richment of Cx40-EGFP-positive cells de-
rived from 6-day-old EBs verified via 
FACS.  b Incidence of beating areas and 
vascular structures derived from unselect-
ed versus highly Cx40-EGFP-positive EBs. 
Each bar represents 24 independent wells, 
into each of which 5 EBs of equal size were 
plated at day 6 and analyzed at day 13 of 
differentiation. 
 Fig. 3. Colocalization of EGFP-positive cells with von Willebrand 
factor (vWF) expression within vascular structures and   -actinin 
expression within beating areas.  a Vascular-like structures at day 
13 of differentiation.  b Immunofluorescent staining of EGFP.
 c Immunofluorescent staining of vWF.  d Overlay of EGFP and 
vWF stainings.  e Beating area at day 13 of differentiation.  f Im-
munofluorescent staining of EGFP.  g Immunofluorescent stain-
ing of   -actinin.  h Overlay of EGFP and   -actinin stainings. Scale 
bar corresponds to 20   m. 
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cardiovascular progenitor cells. We chose day 6 of differ-
entiation at which time point Cx40-controlled EGFP ex-
pression had reached a submaximal level as described 
above ( fig. 2 e). To avoid FACS purification, which is 
harmful for further differentiation of ES cells when per-
formed after differentiation day 3 [David et al., 2005], we 
chose a manual selection protocol based on EGFP fluo-
rescence under the stereomicroscope. We thereby used a 
20-  l pipette to select for highly EGFP-positive EBs in 
suspension culture such as shown for 1 EB in  figure 2 a. 
Using this rather crude method we were able to enrich the 
EGFP-positive fraction approximately 3-fold ( fig. 4 a). 
Correspondingly, after further differentiation until day 
13, beating cardiomyocytes appeared with a 2- to 3-fold 
higher incidence than in unselected EBs and similar re-
sults were obtained for the appearance of vascular-like 
structures ( fig. 4 b). Beating frequencies ranged from 50 
to 80 bpm and did not differ between the selected and 
unselected EBs as well as untransfected controls (data not 
shown).
 We next sought to verify these observations on the 
mRNA level with respect to specific marker expression. 
Thereby, semiquantitative RT-PCRs confirmed an en-
hanced cardiovascular differentiation after FACS puri-
fication based on Cx40-EGFP expression as shown for 
the cardiac markers Nkx2.5 and MLC2v as well as
the endothelial marker vascular endothelial cadherin 
( fig. 5 ).
 Discussion 
 Cardiovascular diseases are the most frequent cause of 
death in the Western world. The critical loss of function-
al cardiomyocytes causes severe deterioration of pump 
function resulting in heart failure. As cardiomyocytes 
cannot be regenerated in adults, current therapeutic mo-
dalities for the treatment of end-stage heart failure are 
limited and include medical therapy, mechanical left ven-
tricular assist devices and cardiac transplantation [Kess-
ler and Byrne, 1999]. The latter is still the treatment of 
choice for end-stage heart failure. However, its applica-
tion is limited by the availability of donor organs and the 
immune response, which requires life-long immunosup-
pressive therapy. Even in case of successful transplanta-
tion, frequent failure of donor organs mainly due to 
transplantation vasculopathy remains still unsolved 
[Hunt, 1998]. The possibility to regenerate or repair dam-
aged or ischemic cardiac and vascular tissue is therefore 
a great challenge for the future.
 So far, ES cells are the only cellular source that have 
been reproducibly shown to differentiate into cardiovas-
cular tissue in vitro, making them a possible future tool to 
repair degenerative cardiovascular diseases [Balsam et al., 
2004; Murry et al., 2004]. In many cases, however, such as 
cardiomyocytes, an appropriate endogenous marker is not 
known, and sorting methods have to rely on the introduc-
tion of a marker gene under the control of a lineage-spe-
cific promoter [David et al., 2005]. Therefore, transgenic 
purification strategies have to be developed to achieve 
high cell numbers for transplantation or cardiovascular 
tissue engineering. For the latter, the availability of cardio-
vascular precursor cells will be of particular interest. Im-
portantly, cardiac and vascular cells share the same em-
bryonic origin within the lateral plate mesoderm [Saga et 
al., 1999] and the heart is the first functional organ of the 
body and begins to pump soon after the vascular system 
of the embryo has established its first circulatory loops 
[Gilbert et al., 2000]. Rather than sprouting from the heart, 
blood vessels form independently, linking up to the heart 
soon afterwards [Larsen, 1998; Gilbert et al., 2000]. The 
rationale for our work was the observation that during de-
velopment, Cx40 is endogenously expressed in cardiogen-
ic cells as well as in the prospective ventricular conduction 
system [Teunissen and Bierhuizen, 2004]. In addition, vas-
culogenic as opposed to smooth muscle cells express Cx40 
[Simon and McWhorter, 2002]. Whereas Cx40 expression 
during mammalian cardiovascular development has been 
well mapped by others [Delorme et al., 1997], our own re-
sults show a very high conservation of Cx40 promoter 
GSES
Nkx2.5
MLC2v
VE-cadh.
H4
–RT
Clone No. 3Clone No. 6
 Fig. 5. Increased expression of cardiovascular markers in Cx40-
EGFP-positive cells. Cells from 2 independent clones were sorted 
via FACS at day 6 of differentiation. mRNA expression of Nkx2.5, 
MLC2v and vascular endothelial cadherin (VE-cadh.) was deter-
mined by RT-PCR incorporating  32 P. Unsorted ES cells served as 
control. 
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specificity even between mammalians and lower verte-
brates. This is confirmed by the functionality of our hu-
man Cx40 promoter construct in the abdominal aorta of 
frog tadpoles after reporter plasmid injection ( fig. 1 b).
 This high conservation of Cx40 promoter regulation 
is also reflected by a significant enrichment of functional 
ES cell-derived cardiomyocytes accompanied by a simul-
taneous increase in vascular cells after transference of 
our novel Cx40 promoter-based approach to ES cells. 
This may become very important for future ES cell-based 
cardiac cell therapy.
 Further, our ES cell-based data reveal that after crude 
manual enrichment of highly Cx40-EGFP-positive EBs, 
which led to an approximately 3-fold enrichment of the 
exact number of Cx40-EGFP-positive cells, the appear-
ance of cardiac and vascular structures was increased by 
the same factor. Again, this shows the high specificity of 
our 4.9-kb promoter construct as observed on the levels 
of phenotypic analysis as well as in extensive RT-PCR 
analyses and protein expression data ( fig. 2 d,  3 ,  4 ).
 Our study aimed to investigate the feasibility of a fu-
ture high-grade purification of cardiovasculogenic cells 
from differentiating EBs using the Cx40 promoter. It 
shows proof of principle that the deleted CD4 (  CD4) 
surface marker-based method for MACS previously de-
scribed by us appears well suitable for transference to this 
promoter [David et al., 2005]. Potential limitations of this 
approach are contaminations with undifferentiated cells, 
which may be tumorigenic, or with undesired cell types 
eventually leading to arrhythmias. On the other hand, 
promoters displaying a very weak activity may lead to 
levels of   CD4 expression too low for an efficient purifi-
cation. However, MACS is currently regarded as the gold 
standard for mild and time-sparing cell purification. Us-
ing MACS, up to 10 11 cells can be analyzed in about 1 h, 
making it possible to separate large cell numbers and 
identify even rare populations of cells.
 We have recently developed this novel technique to 
overcome the obstacles associated with alternative ap-
proaches relying on cytometry, which is slow and typi-
cally capable of analyzing no more than 3,000 cells/s. To 
achieve cell numbers required for transplantations into 
humans ( 1 10 8 cells in the case of cardiomyocytes), a pu-
rification period of more than 500 h would be necessary. 
Therefore, FACS does not appear to provide the capabili-
ties to identify a rare population of cells or to separate 
large numbers of cells due to the excessive amount of 
analysis and sorting time [David et al., 2005]. Likewise, 
approaches relying on the introduction of drug resistance 
genes for antibiotic selection [Klug et al., 1996; Zandstra 
et al., 2003] are critical because of the long incubation 
period with the hazard of resistance and possible harmful 
effects of the antibiotic on terminally differentiated cells 
themselves. Additionally, FACS sorting based on fluores-
cent markers as well as antibiotic selection are based on 
the expression of nonhuman proteins that may cause ad-
ditional immunological problems or even be toxic in pa-
tients.
 Due to our encouraging data and the urgent need of 
cardiovasculogenic cell material as a basis for tissue en-
gineering and cell transplantation studies, we will now 
combine the   CD4-based MACS technique with the 
Cx40 promoter approach. Thereby, we will generate sta-
ble human ES cell lines bearing the Cx40-  CD4 promot-
er construct in order to dispose of human cardiovasculo-
genic cell material valuable in preclinical studies using 
immunodeficient mice as recipients. Likewise, the Cx40-
positive cells selected via this gentle MACS-based meth-
od will be used for detailed functional characterization 
with respect to their pharmacological and electrophysi-
ological properties. These are likely to be affected in the 
FACS-sorted cells used in our initial work reported here. 
Furthermore, it will be of great interest to transfer the 
Cx40-  CD4-based approach to the recently described 
spermatogonial stem cells [Guan et al., 2006] as well as to 
stem cells derived from reprogrammed somatic cells 
[Takahashi and Yamanaka, 2006; Park and Daley, 2007; 
Takahashi et al., 2007; Wernig et al., 2007]. This may be 
the basis for future autologous cellular sources and future 
clinical use of Cx40 promoter-purified cardiovascular 
progenitor cells.
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